NuSep erects NxGen prospectus
Thursday, 12 March, 2009
NuSep has issued a prospectus for its reverse takeover of sexual dysfunction specialist NxGen Pharmaceuticals.
NuSep is looking to raise $5 million by offering 100 million shares at 5c. It will hold an EGM tomorrow to approve the acquisition.
The NuSep plan is to divest its electrophoresis gel and sperm separation business into a new company called Prime BioSeparations.
NuSep supplies the gels to the life science research market and is completing clinical trials of a sperm sorting machine for the IVF market. It also fractionates plasma products for the research sector.
NxGen is into sexual dysfunction, premature ejaculation and drug addiction. It supplies a nasal spray for erectile dysfunction and a naltrexone implant for alcohol, nicotine and opiate addiction.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
